Georges Weissgerber

1.2k total citations · 1 hit paper
21 papers, 884 citations indexed

About

Georges Weissgerber is a scholar working on Ophthalmology, Molecular Biology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Georges Weissgerber has authored 21 papers receiving a total of 884 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Ophthalmology, 7 papers in Molecular Biology and 7 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Georges Weissgerber's work include Retinal Diseases and Treatments (10 papers), Retinal Imaging and Analysis (7 papers) and Retinal and Optic Conditions (4 papers). Georges Weissgerber is often cited by papers focused on Retinal Diseases and Treatments (10 papers), Retinal Imaging and Analysis (7 papers) and Retinal and Optic Conditions (4 papers). Georges Weissgerber collaborates with scholars based in Switzerland, United States and United Kingdom. Georges Weissgerber's co-authors include Frank G. Holz, Ramin Tadayoni, Pravin U. Dugel, Ursula Schmidt‐Erfurth, Kinfemichael Gedif, Yuichiro Ogura, Glenn J. Jaffe, Adrian Koh, Rishi P. Singh and Laura Sararols and has published in prestigious journals such as Clinical Cancer Research, Ophthalmology and British Journal of Cancer.

In The Last Decade

Georges Weissgerber

21 papers receiving 855 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

HAWK and HARRIER

2020 260 citations Pravin U. Dugel, Rishi P. Singh et al. Ophthalmology profile →

Peers

Countries citing papers authored by Georges Weissgerber

Since Specialization

Citations

This map shows the geographic impact of Georges Weissgerber's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Georges Weissgerber with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Georges Weissgerber more than expected).

Fields of papers citing papers by Georges Weissgerber

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Georges Weissgerber. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Georges Weissgerber. The network helps show where Georges Weissgerber may publish in the future.

Co-authorship network of co-authors of Georges Weissgerber

This figure shows the co-authorship network connecting the top 25 collaborators of Georges Weissgerber. A scholar is included among the top collaborators of Georges Weissgerber based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Georges Weissgerber. Georges Weissgerber is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A Randomized, Double-Masked, Multicenter Trial of Topical Acrizanib (LHA510), a Tyrosine Kinase VEGF-Receptor Inhibitor, in Treatment-Experienced Subjects With Neovascular Age-Related Macular Degeneration 2022 ·American Journal of Ophthalmology ·Stephen Poor, Georges Weissgerber, Christopher M. Adams, (unknown), David J. Browning, James E. Chastain, Thomas A. Ciulla, (unknown), Kinfemichael Gedif, Louis C. Glazer, Brian C. Joondeph, Guillaume Normand, Veeral Sheth, (unknown), Cynthia L. Grosskreutz	13
2	Therapeutic response in the HAWK and HARRIER trials using deep learning in retinal fluid volume and compartment analysis 2022 ·Eye ·Ursula Schmidt‐Erfurth, Zufar Mulyukov, Bianca S. Gerendas, Gregor S. Reiter, (unknown), Georges Weissgerber, Hrvoje Bogunović	29
3	Topical Anti-TNFα Agent Licaminlimab (OCS-02) Relieves Persistent Ocular Discomfort in Severe Dry Eye Disease: A Randomized Phase II Study 2022 ·Clinical ophthalmology ·(unknown), Eugene McLaurin, (unknown), (unknown), Georges Weissgerber	12
4	Topical Ocular Anti-TNFα Agent Licaminlimab in the Treatment of Acute Anterior Uveitis: A Randomized Phase II Pilot Study 2022 ·Translational Vision Science & Technology ·(unknown), Melissa Toyos, David B. Abrams, David K. Scales, (unknown), Georges Weissgerber	1
5	Efficacy and safety of brolucizumab versus aflibercept in eyes with polypoidal choroidal vasculopathy in Japanese participants of HAWK 2021 ·British Journal of Ophthalmology ·Yuichiro Ogura, Glenn J. Jaffe, Chui Ming Gemmy Cheung, Gregg T. Kokame, Tomohiro Iida, Kanji Takahashi, Won Ki Lee, Andrew Chang, Jordi Monés, (unknown), Georges Weissgerber, Kinfemichael Gedif, Adrian Koh	37
6	EFFECT OF RETINAL THICKNESS VARIABILITY ON VISUAL OUTCOMES AND FLUID PERSISTENCE IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION 2021 ·Retina ·Pravin U. Dugel, Chirag Jhaveri, Usha Chakravarthy, Charles C. Wykoff, Rishi P. Singh, Robin Hamilton, Georges Weissgerber, Zufar Mulyukov, Frank G. Holz	11
7	A comparison of the therapeutic response between brolucizumab and aflibercept in the HAWK & HARRIER trials using deep learning-based OCT analysis 2020 ·Investigative Ophthalmology & Visual Science ·Ursula Schmidt‐Erfurth, Zufar Mulyukov, Bianca S. Gerendas, Philippe Margaron, (unknown), Hrvoje Bogunović, Georges Weissgerber	3
8	HAWK and HARRIER breakdown → 2020 ·Ophthalmology ·Pravin U. Dugel, Rishi P. Singh, Adrian Koh, Yuichiro Ogura, Georges Weissgerber, Kinfemichael Gedif, Glenn J. Jaffe, Ramin Tadayoni, Ursula Schmidt‐Erfurth, Frank G. Holz	260
9	Use of Composite End Points in Early and Intermediate Age-Related Macular Degeneration Clinical Trials: State-of-the-Art and Future Directions 2020 ·Ophthalmologica ·Jan Henrik Terheyden, Steffen Schmitz-Valckenberg, David P. Crabb, Hannah Dunbar, Ulrich F. O. Luhmann, Charlotte Behning, Matthias Schmid, Rufino Silva, José Cunha‐Vaz, Adnan Tufail, Georges Weissgerber, Sérgio Leal, Frank G. Holz, Robert P. Finger	6
10	Brolucizumab: A Newly Developed Anti-VEGF Molecule for the Treatment of Neovascular Age-Related Macular Degeneration 2020 ·Ophthalmologica ·Ramin Tadayoni, Laura Sararols, Georges Weissgerber, (unknown), Andreas Clemens, Frank G. Holz	100
11	Prediction of Geographic Atrophy progression by deep learning applied to retinal imaging 2019 ·Guillaume Normand, Gwenolé Quellec, Ronan Danno, Bruno Laÿ, Georges Weissgerber, Nadia Zakaria, Sudeep Chandra	2
12	Visual and expanded anatomical outcomes for brolucizumab versus aflibercept in patients with neovascular AMD: 96-week data from HAWK and HARRIER 2019 ·Rishi P. Singh, Charles C. Wykoff, Ramin Tadayoni, Yuichiro Ogura, Adrian H. Koh, Frank G. Holz, Robin Hamilton, David J. Tanzer, Georges Weissgerber, (unknown), Pravin U. Dugel	4
13	Single-Chain Antibody Fragment VEGF Inhibitor RTH258 for Neovascular Age-Related Macular Degeneration 2016 ·Ophthalmology ·Frank G. Holz, Pravin U. Dugel, Georges Weissgerber, Robin Hamilton, Rufino Silva, Francesco Bandello, Michael Larsen, Andreas Weichselberger, Andreas Wenzel, Anne Schmidt, Dominik Escher, Laura Sararols, Eric H. Souied	133
14	Effects of ketoconazole and valproic acid on the pharmacokinetics of the next generation NNRTI, lersivirine (UK‐453,061), in healthy adult subjects 2011 ·British Journal of Clinical Pharmacology ·Grant Langdon, John D. Davis, Gary Layton, (unknown), Georges Weissgerber, Manoli Vourvahis	11
15	The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of RO5068760, an MEK Inhibitor, in Healthy Volunteers: Assessment of Target Suppression 2010 ·The Journal of Clinical Pharmacology ·(unknown), Huifeng Niu, Petra Goelzer, Ruediger Rueger, Jonathan Deutsch, (unknown), (unknown), (unknown), Joanne Barrett, Georges Weissgerber, Richard Peck	8
16	The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of CH4987655 in Healthy Volunteers: Target Suppression Using a Biomarker 2009 ·Clinical Cancer Research ·(unknown), Huifeng Niu, Ruediger Rueger, (unknown), Jonathan Deutsch, Nobuya Ishii, Song Mu, (unknown), (unknown), Claude Gimmi, Petra Goelzer, Stefanie De Schepper, (unknown), Joanne Barrett, Yuji Ishikawa, Georges Weissgerber, Richard Peck	30
17	Effect of single doses of maraviroc on the QT/QTc interval in healthy subjects 2008 ·British Journal of Clinical Pharmacology ·John D. Davis, Frances Hackman, Gary Layton, Tracy Higgins, (unknown), Georges Weissgerber	23
18	Cognitive testing in early-phase clinical trials: Development of a rapid computerized test battery and application in a simulated Phase I study 2006 ·Contemporary Clinical Trials ·Alex Collie, Amanda Darekar, Georges Weissgerber, Melvin Toh, Peter J. Snyder, Paul Maruff, John P. Huggins	68
19	Protein kinase C in human renal cell carcinomas: role in invasion and differential isoenzyme expression 2000 ·British Journal of Cancer ·Rainer Engers, (unknown), E Springer, Doriano Fabbro, Georges Weissgerber, (unknown), H. Gabbert	49
20	Activation of protein kinase C subtypes α, γ, δ, ϵ, ζ, and η by tumor-promoting and nontumor-promoting agents 1997 ·Biochemical Pharmacology ·(unknown), Thomas Meyer, Barbara Marte, (unknown), Georges Weissgerber, Silvia Stabel, Josef Pfeilschifter, (unknown), Andrea Huwiler	79

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact